BioLineRX Ltd. · TASE:BLRX
BioLineRX — Investor Presentation (October 2018)
30 slides from BioLineRX's investor presentation, Oct 1, 2018

Slide 1: Transforming science into medicine
Transforming science into medicine

Slide 2: Forward-looking statements
2 Forward-looking statements This presentation contains “forward-looking statements.” These statements include words like “may,” “expects,” “believes,” “plans,” “scheduled,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and

Slide 3: Our Mission
3 Our Mission Our mission is to become a leader in the development of novel therapeutics for the treatment of cancer

Slide 4: Who Are We?
4 Who Are We? Ticker / Exchange BLRX (NASDAQ) Headquarters Tel Aviv, Israel Market cap ~$140 million (1-Oct-18) Shares outstanding ~108 million Cash ~$41.1 million (30-Jun-18) Cash runway Through 1H 2020 Employees ~55 (~40 in R&D) NASDAQ: BRLX

Slide 5: Investment Highlights
5 Investment Highlights ➢ Large-market indications with unmet medical needs Singular focus on ➢ Phase 3: stem cell mobilization oncology ➢ Phase 2: AML, pancreatic, gastric ➢ Nine mid-to-late stage studies ongoing Multiple opportunities ➢ 3-4 data readouts over next 12 months for value creation ➢ Ph

Slide 6: Leadership Team
6 Leadership Team Seasoned executives with decades of experience in medicine, drug development, clinical studies, and financial and corporate development Philip A. Serlin, CPA, MBA Chief Executive Officer Mali Zeevi, CPA Chief Financial Officer Hillit Mannor Shachar, MD, MBA, VP of Business Developm

Slide 7: A Diverse Pipeline Targeting Multiple Oncology Indications
7 A Diverse Pipeline Targeting Multiple Oncology Indications REGULATORY PROJECT INDICATION PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVAL CANCER BL-8040 Stem-cell mobilization Relapsed/refractory AML Consolidation AML Maintenance AML Gastric cancer Non-small cell lung cancer Pancreatic cancer Pancrea

Slide 8: BL-8040 – Best-In-Class CXCR4 Antagonist for Multiple Oncology and Hematology Indications
BL-8040 – Best-In-Class CXCR4 Antagonist for Multiple Oncology and Hematology Indications For treatment of solid tumors, AML and indications requiring hematopoietic stem cell transplantation

Slide 9: BL-8040 – A Best-in-Class CXCR4 Antagonist Targeting Multiple Indications
9 BL-8040 – A Best-in-Class CXCR4 Antagonist Targeting Multiple Indications A 14-amino acid synthetic cyclic peptide, high-affinity CXCR4 antagonist with long receptor occupancy (>48 hours) and extended CXCR4 inhibition Phase 3 Phase 2 Phase 1 & 2 Stem Cell Mobilization Acute Myeloid Leukemia Cancer

Slide 10: Stem Cell Mobilization
10 Stem Cell Mobilization BL-8040 in Stem Cell Mobilization

Slide 11: Stem-Cell Mobilization For Patients Undergoing Bone-Marrow Transplantation
11 Stem-Cell Mobilization For Patients Undergoing Bone-Marrow Transplantation Patients with hematological malignancies often require HSC transplant after treatment to restore their immune system Significant unmet medical need in SCM • Multiple apheresis sessions required • 50-70% of patients are poo

Slide 12: GENESIS Phase 3 Study: Mobilization of HSCs in Multiple Myeloma Patients
12 GENESIS Phase 3 Study: Mobilization of HSCs for Autologous Transplant in Multiple Myeloma Patients Initiated Q4 2017 - Phase 3 randomized, placebo-controlled, safety and efficacy study (n=177): NCT03246529 Study design BL-8040 potentially offers patients: Part 1: Lead-in period - dose confirmatio

Slide 13: BL-8040 in AML
BL-8040 in AML BIOLINEM>X<

Slide 14: BL-8040's Potential Role in the AML Treatment Pathway
14 BL-8040’s Potential Role in the AML Treatment Pathway – Sensitizing Leukemic Cells to Anti-Cancer Therapies Malignant cells are harbored within protected niches in the bone marrow (minimal residual disease), which impacts remission and survival rates BL-8040 mobilizes AML cells to the peripheral

Slide 15: BL-8040.01 Phase 1/2a Study in Relapsed/Refractory AML
15 BL-8040.01 Phase 1/2a Study: Encouraging Results in Patients with Relapsed/Refractory AML Phase 1/2a dose escalation/expansion study (n=42): NCT01838395 Study design Comparison of the composite response rate Dose escalation (0.5 to 2.0 mg/kg) with expansion cohort at 1.5mg/kg (CR + CRi) of BL-804

Slide 16: BLAST Phase 2b Study: Consolidation Therapy for AML
16 BLAST Phase 2b Study: Consolidation Therapy for AML Patients in First Remission Phase 2b double-blind, multi-center placebo controlled study (n=194): NCT02502968 Treatment: Two or three cycles (age-based) of high-dose Ara-C in combination with either BL-8040 or placebo Endpoints BL-8040 potential

Slide 17: BL-8040 in Cancer Immunotherapy
BL-8040 in Cancer Immunotherapy

Slide 18: BL-8040 – Addressing Unmet Needs in Cancer Immunotherapy
18 BL-8040 – Addressing Unmet Needs in Cancer Immunotherapy Despite significant advances in cancer BL-8040 addresses these needs by: immunotherapy, material needs remain: Improving efficacy of immunotherapy in Mobilizing immune cells to peripheral blood “cold” tumors, such as pancreatic cancer circu

Slide 19: Data Supporting Role of BL-8040 in Immunotherapy
19 Data Supporting Role of BL-8040 in Immunotherapy Robust mobilization Tumor infiltration1 Microenvironment modification Pre-treatment Healthy volunteers were treated with CXCR4 antagonism selectively inhibits BL-8040 or placebo the migration of immunosuppressive cells Single administration of BL-8

Slide 20: Ongoing Collaborations with Global Pharma Companies Validate BL-8040
20 Ongoing Collaborations with Global Pharma Companies Validate BL-8040’s Novel Mechanism of Action NCT02826484, NCT03193190, NCT03281369, NCT03154827 COMBAT Phase 2a study for BL-8040 + Four phase 1/2 studies planned for BL-8040 + pembrolizumab (Keytruda®) atezolizumab (TecentriqTM) Study in metast

Slide 21: COMBAT Phase 2a Study in Advanced Pancreatic Cancer
21 COMBAT Phase 2a Study in Advanced Pancreatic Cancer Phase 2a open-label, multi-center study in combination with pembrolizumab (n=37): NCT02826484 To assess the safety and efficacy of BL-8040 in combination with pembrolizumab (Keytruda) in patients with advanced pancreatic cancer Endpoints Interme

Slide 22: AGI-134 – Cancer Immunotherapy
AGI-134 – Cancer Immunotherapy A universal anti-cancer vaccine with a unique mechanism of action

Slide 23: Alpha-Gal and Anti-Gal
23 Alpha-Gal and Anti-Gal The alpha-Gal epitope is abundantly synthesized on glycolipids of non-primates while absent in human Due to constant exposure to this antigen (expressed by gut flora) humans develop and maintain high levels of anti-Gal Abs Xenotransplantation experiments in the 1980’s-90’s

Slide 24: AGI-134 Induces a Potent Patient-Specific Anti-Tumor Immune Response
24 AGI-134 Induces a Potent Patient-Specific Anti-Tumor Immune Response AGI-134 is being developed to realize the therapeutic potential of alpha-Gal/anti-Gal immunology ▪ Tumors vary from patient to patient in their neoantigen load and identity ▪ AGI-134 is a fully synthetic alpha-Gal glycolipid mol

Slide 25: AGI-134 Induces Regression of Established Melanoma Tumors in Mice
25 Intratumoral Treatment with AGI-134 Induces Regression of Established Melanoma Tumors in Mice Administration of AGI-134 induced regression of established primary tumors Days post inoculation ASCO-SITC 2018 Abstract 68 / poster E4

Slide 26: AGI-134 Exerts a Potent Durable Abscopal Effect
26 AGI-134 Exerts a Potent Durable Abscopal Effect Single dose of AGI-134 into primary tumor protected mice from secondary tumor development for more than 90 days Synergistic effect demonstrated in combination of AGI-134 with immune checkpoint inhibitor Inoculate melanoma cells Treat 1° tumor Monito

Slide 27: Outline of Ongoing Phase 1/2a Clinical Study of AGI-134
High Level Outline of Ongoing Phase 1/2a Clinical Study AGI-134 27 Open-label study to evaluate the safety and tolerability of AGI-134 as monotherapy and in combination with AGI-134+ICI pembrolizumab, in unresectable metastatic solid tumors (NCT03593226) PART 1 PART 2 Accelerated escalation monother

Slide 28: Looking ahead
Looking ahead BIOLINEP>*<

Slide 29: Recent Accomplishments and Upcoming Milestones
29 Recent Accomplishments and Upcoming Milestones Multiple opportunities for value creation BL-8040 Partial results from Phase 2a COMBAT pancreatic cancer study (with Merck) 1Q 2018 BL-8040 Top-line results from Phase 2 allogenic stem cell mobilization (Auto SCM) study 2Q 2018 AGI-134 Initiation of

Slide 30: Key Takeaways
30 Key Takeaways ➢ Large-market indications with unmet medical needs Singular focus on ➢ Phase 3: stem cell mobilization oncology ➢ Phase 2: AML, pancreatic, gastric ➢ Nine mid-to-late stage studies ongoing Multiple opportunities ➢ 3-4 data readouts over next 12 months for value creation ➢ Phase 3 r
Source: Internet Archive copy of biolinerx.com
More decks from BioLineRX Ltd.
Investor Presentation (July 2026)39 slides · July 2026
Q1 2026 Earnings Presentation28 slides · May 27, 2026
Technical Presentation (December 2020)14 slides · Dec 16, 2020
Technical Presentation (December 2020)49 slides · Dec 16, 2020
Investor Presentation (February 2019)31 slides · Feb 4, 2019
Investor Presentation (June 2018)32 slides · June 2018